Navigation Links
Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Date:8/22/2007

s biology approach to drug development, combining pharmacogenomics and bioinformatics with experienced preclinical, clinical, and regulatory expertise to find and exploit a specific cancer's 'context-of-vulnerability.' Specifically, SM defines the molecular and genetic alterations (context) that cause cancer cells to be particularly sensitive (vulnerable) to a drug or combination of drugs-the 'context-of-vulnerability'.

About the National Cancer Institute's Center for Cancer Research Nanobiology Program

The National Cancer Institute (NCI), part of the NIH, an agency under the U.S. Department of Health and Human Services, is the world's pre-eminent cancer research organization. The NCI engages in certain fundamental activities which include: conducting and fostering cancer research; reviewing and approving grant-in-aid applications to support promising research projects on the causes, prevention, diagnosis, and treatment of cancer; collecting, analyzing, and disseminating the results of cancer research conducted in the United States and elsewhere; and training and instruction in the diagnosis and treatment of cancer. The Center for Cancer Research Nanobiology Program (CCRNP) serves as a catalyst to move forward multidisciplinary efforts in the area of Cancer Nanotechnology. The program forms partnerships with the NCI's broader Nanotechnology Program, other CCR basic research laboratories and clinical branches, as well as with the broader extramural community, to enhance the interface of physics and computational sciences with biology.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the success of developments realized by SM under the CRADA, SM's ability to successfully negotiate for the rights to further develop, market and sell any products that are
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
2. prostar RT-PCR Systems for Robust High-Fidelity RNA Amplification
3. Performance Comparisons of Commercial RT-PCR Systems
4. Signal Transduction Reporting Systems Using Cis-Acting Enhancer Elements
5. In Vivo Signal Transduction Pathway Reporting Systems
6. Improved Vectors for PathDetect Trans-Reporting Systems
7. Genetic Reporter Systems
8. Genetic Reporter Systems
9. Matched siRNAs and Assays: Ambion + Applied Biosystems = RNAi Success
10. Separation Reproducibility With the BioLogic Chromatography Systems
11. Preparative SDS-PAGE Electrophoresis of a Recombinant Epstein-Barr Virus Encoded Protein and Its Application in Serodiagnostic Test Systems, Rev C
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Bacteria provide new insights into human decision making 2Bacteria provide new insights into human decision making 3Bacteria provide new insights into human decision making 4Bacteria provide new insights into human decision making 5Case Western Reserve University grants option to startup Thermalin Diabetes Inc. 2Scientists identify natural anti-cancer defenses 2FreedomVOICE Proposes Telecommuting to Tackle the H1N1 Virus 60789 1FreedomVOICE Proposes Telecommuting to Tackle the H1N1 Virus 60789 2FreedomVOICE Proposes Telecommuting to Tackle the H1N1 Virus 60789 3FreedomVOICE Proposes Telecommuting to Tackle the H1N1 Virus 60789 4Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 1Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 2Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 3Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 4Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 5Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 6Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 7Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 8Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 9Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 10Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 11Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 12Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 13Volcano Reports 22 Percent Increase in Third Quarter Revenues 60786 14DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 14743 1DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 14743 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 14743 3